

Special Issue

Neutrophilic Inflammation: Molecular Mechanisms and Drug Discovery

Message from the Guest Editors

The Special Issue "Neutrophilic Inflammation: Molecular Mechanisms and Drug Discovery" aims to provide a comprehensive overview of the molecular mechanisms underlying neutrophilic inflammation, as well as the current state of drug discovery efforts targeting this process. Neutrophilic inflammation plays a critical role in the pathogenesis of various diseases, including acute respiratory distress syndrome, chronic obstructive pulmonary disease sepsis, rheumatoid arthritis, psoriasis, systemic lupus erythematosus, and cancer. The Special Issue will cover a broad range of topics, including neutrophil recruitment and activation, signaling pathways, the role of neutrophils in tissue damage and repair, and the development of novel therapeutic strategies. The ultimate goal is to promote a better understanding of the complex biology of neutrophilic inflammation and to facilitate the identification of new drug targets for treating inflammatory diseases. The Issue welcomes original research articles, reviews, and perspectives that cover any aspect of neutrophilic inflammation and drug discovery.

Guest Editors

Dr. Po-Jen Chen

Department of Medical Research, E-Da Hospital, Kaohsiung 824410, Taiwan

Dr. Kuei-Hung Lai

Program in the Clinical Drug Development of Herbal Medicine, Taipei Medical University, Taipei 11031, Taiwan

Deadline for manuscript submissions

closed (31 December 2023)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/167550

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).